Drug Trial Radar · NCT06907290
A Trial Evaluating BJT-778 vs Delayed Treatment for the Treatment of Chronic Hepatitis Delta Infection
Last checked: Nov 19, 2026Latest source record: Oct 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
150
Planned (sponsor's estimate)
Start
Mar 25, 2025
Primary completion
May 2029
Study completion Sep 2029
Sponsor
- Lead sponsor
- Mirum Pharmaceuticals, Inc.Industry
- Sponsor type
- Industry
- First posted
- Apr 2, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 2b/3 study designed to evaluate the safety and efficacy of chronic treatment with brelovitug (a.k.a BJT-778; BTG) for chronic hepatitis delta virus (HDV) infection. The comparator in this study will be 24-weeks of delayed treatment. During the 24-weeks of delayed treatment, participants will complete the same visits and assessments as those randomized to initiate brelovitug immediately. At the completion of 24-week delayed treatment period, all participants will start treatment with brelovitug.
Conditions
- Chronic Hepatitis D Infection
Interventions
Brelovitug 300 mgDrug
Route of administration- Subcutaneous Injection
Brelovitug 900 mgDrug
Route of administration- Subcutaneous Injection
Delayed Treatment with Brelovitug 300mgDrug
Route of administration- Subcutaneous Injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of participants with a composite endpointTime frame: Week 24
Locations
30 sites in 11 countries. Site status is shown where the registry gives one.
252 Long Beach
Long Beach, California
244 Los Angeles
Los Angeles, California
251, Illinois
Chicago, Illinois
248 Lowa
Cities in Iowa, Iowa
254 Baltimore
Baltimore, Maryland
245 New York
New York, New York
256 New York
New York, New York
253 New York
New York, New York
255 New York
New York, New York
257 Philadelphia
Philadelphia, Pennsylvania
101 Camperdown
Camperdown, Australia
104 Liverpool
Liverpool, Australia
102 Melbourne
Melbourne, Victoria, Australia
705 Plovdiv
Plovdiv, Bulgaria
704 Stara Zagora
Stara Zagora, Bulgaria
703 Sliven
Sliven, Silven, Bulgaria
233 Calgary
Calgary, Calgary, Canada
234 Alberta
Edmonton, Edmonton, Canada
231 Toronto
Toronto, Ontario, Canada
235 Montreal
Montreal, Quebec, Canada
181 Tbilisi
Tbilisi, Georgia
183 Tbilisi
Tbilisi, Georgia
182 Tbilisi
Tbilisi, Georgia
211 Israel
Beersheba, Israel
212 Haifa
Haifa, Haifa District, Israel
901 Chisinau
Chisinau, Moldova
001 Auckland
Auckland, New Zealand
221 Karachi City
Karachi, Karachi, Pakistan
191 Istanbul
Istanbul, Istanbul, Turkey (Türkiye)
110 Kyiv
Kyiv, Ukraine
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.